Juergen’s career spans three decades and covers a broad therapeutic range of planning and hands-on execution of nonclinical and all phases of clinical drug development such as cystic fibrosis, bronchiectasis, acromegaly, OTC deficiency, cervical dystonia, acute stroke, acute coronary syndrome and diabetic nephropathy. He has worked with biologics, macrocycles, peptides, small molecules and RNA therapeutics at small, mid-size and large companies, like Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers-Squibb, Ipsen, Vertex, Aradigm Corporation, Genevant and EnBiotix Inc/Spexis AG. In several assignments as Chief Medical or Chief Development Officer, he actively participated in successful fundraising activities. Juergen was instrumental in critical regulatory interactions and obtaining marketing authorizations in the U.S., Canada, the E.U., Switzerland and Australia. He is a board member of Appili Therapeutics in Canada, a public company focusing on prevention and treatment of a broad spectrum of infectious diseases.

At Genevant, Juergen created the clinical development programs plans to utilize mRNA or siRNA molecules for OTC deficiency, acromegaly and RNA targets for other liver diseases. He also oversaw the toxicology programs for these development projects. At Vertex, as Head of Regulatory Affairs and Clinical Regulatory Strategy, Juergen hands-on supported the NDA, MAA and other regulatory submissions/approvals for Kalydeco® and participated in regulatory interactions with the FDA on development planning for follow-on CFTR modulators. Since 2013 he has been involved in early and late-stage development of inhaled therapeutics, including the planning and conduct of Ph 1-3 trial programs with colistin, murepavadin and liposomal ciprofloxacin in patients with cystic fibrosis (CF) or bronchiectasis and chronic Pseudomonas aeruginosa lung infection. He was an invited panel member at a U.S. Food and Drug Administration workshop in 2018 for inhaled antibiotics in CF and bronchiectasis.

Juergen earned his MD from Wuerzburg University in Germany and his dual executive MBA degree from the Graduate School of Business Administration in Switzerland and the State University of New York at Albany. He is a Fellow of the American College of Clinical Pharmacology and a diplomate of the American Board of Clinical Pharmacology.